Wegovy Starting Dose: What Your Doctor Will Prescribe

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

When a doctor initiates semaglutide for weight loss or blood sugar control, the starting dose is deliberately modest—typically 0.25 mg per week—to allow your body to adjust and reduce nausea. Most treatment plans follow a four-step titration ladder over 16 weeks before reaching a maintenance dose that works for your metabolism and health goals.

Standard Semaglutide Starting Dose Schedule

The FDA-approved Wegovy protocol begins at 0.25 mg injected once weekly for the first four weeks. This micro-dose activates your GLP-1 receptors gradually, signaling satiety to your brain without overwhelming your digestive system. Most patients tolerate this entry point well, though mild nausea or appetite suppression can occur as your body adapts.

After four weeks at 0.25 mg, the dose typically increases to 0.5 mg weekly for another month. By week eight, many patients move to 1 mg per week as their tolerance improves and clinical response is assessed. Each step builds on the previous one, allowing doctors to monitor how your weight, blood sugar, and side-effect profile respond before advancing further.

The Four-Week Titration Ramp and Maintenance Goals

Clinical trials show that stepping up semaglutide in four-week increments—from 0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg—mirrors how the body's GLP-1 signaling network reaches optimal sensitivity. This 16-week ramp reduces discontinuation due to side effects by up to 30% compared to faster titration protocols. Your doctor adjusts the timeline based on your tolerance, comorbidities, and weight-loss velocity.

Maintenance doses range from 1.0 to 2.4 mg weekly, depending on individual response and clinical need. Some patients achieve their goal weight at 1.0 mg and remain there indefinitely; others require the full 2.4 mg dose for sustained benefit. PlexusDx practitioners use your starting response to forecast which maintenance range will work best for your metabolism.

Why Doctors Start Low and Go Slow

Beginning semaglutide at 0.25 mg is not about insufficient efficacy—it is about maximizing adherence and safety. The GLP-1 receptor system controls appetite, gastric emptying, and blood sugar simultaneously; flooding it with a high dose causes nausea, vomiting, and food aversion that often lead patients to quit treatment. Low-and-slow titration lets your brain's satiety circuits recalibrate without overwhelming your GI tract.

Research published in obesity journals confirms that patients who tolerate low starting doses have better long-term weight loss and lower rates of serious adverse events. Kidney function, blood pressure, and pancreatic markers remain stable when titration is gradual. This conservative approach also reduces the risk of discontinuing due to intolerable side effects, a leading cause of treatment failure in GLP-1 therapy.

Compounded Semaglutide Dosing at PlexusDx

PlexusDx provides FDA-grade semaglutide from licensed 503A compounding pharmacies, available in all 50 states without insurance or membership fees. Your starting dose follows the same evidence-based titration as Wegovy: beginning at 0.25 mg weekly and advancing every four weeks based on your clinical response. HSA and FSA plans cover PlexusDx compounded semaglutide, reducing out-of-pocket costs for eligible patients.

PlexusDx pricing remains flat at $149/month regardless of your dose level—whether you are at 0.25 mg or 2.4 mg. This removes the financial barrier that sometimes discourages patients from titrating up when clinically indicated. After your first month of treatment, the optional Precision Peptide Genetic Test ($99 add-on) maps your GLP1R and other peptide-pathway variants to forecast your individual dose-response profile and long-term adherence potential.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the very first dose of semaglutide I will receive?

Your first injection will typically be 0.25 mg administered once per week. This starter dose is intentionally small to let your body adapt to GLP-1 signaling and minimize nausea. After four weeks, your doctor will assess your tolerance and response before moving to the next tier.

How fast can my semaglutide dose increase?

Standard practice increases the dose every four weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. However, if you experience significant side effects, your doctor can extend the interval or hold at one dose longer. Faster titration may be possible in some cases, but slower progression consistently achieves better long-term outcomes and adherence.

Does PlexusDx charge more if my dose goes higher?

No. PlexusDx compounded semaglutide starts at $149/month and remains at that flat rate across all dose levels. Your dose may need to go up—your price won't. This pricing model ensures you can titrate to your optimal therapeutic dose without financial hesitation.

What side effects should I expect when starting semaglutide?

Mild to moderate nausea, reduced appetite, and occasional constipation are common during the first 1–4 weeks at low doses. These effects typically subside as your body adjusts. Serious side effects such as pancreatitis or thyroid concerns are rare; your PlexusDx provider monitors your kidney function and vital signs throughout treatment to ensure safety.

Can the Precision Peptide Genetic Test predict my ideal starting dose?

The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways and 150+ genetic insights, including your GLP1R variant (rs6923761) and FTO genetic predispositions. While all patients start at 0.25 mg, your genetic profile helps your doctor anticipate whether you will respond robustly at lower doses or require the full titration sequence, personalizing your treatment timeline.

Related Reading

• Victoza Starting Dose
• Trulicity Starting Dose
• Liraglutide Starting Dose
• Glp 1 Starting Dose

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.